{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:24:53Z","timestamp":1793121893680,"version":"4.5.0"},"reference-count":23,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2024,11,30]]},"DOI":"10.5582\/irdr.2024.01056","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T22:13:27Z","timestamp":1732918407000},"page":"227-235","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of the safety and efficacy of miglustat for the treatment of Chinese patients with Niemann-Pick disease type C: A prospective, open-label, single-arm, phase IV trial"],"prefix":"10.5582","volume":"13","author":[{"given":"Huiwen","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pediatric Endocrinology\/Genetics, Shanghai Institute For Pediatric Research, Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Peking University First Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuijie","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Peking University First Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengni","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology\/Genetics, Shanghai Institute For Pediatric Research, Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Che","sequence":"additional","affiliation":[{"name":"Medical Affairs, Xi&apos;an Janssen Pharmaceutical Ltd., Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Statistics &amp; Decision Science, Janssen China R&amp;D, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyu","family":"Li","sequence":"additional","affiliation":[{"name":"Medical Affairs, Xi&apos;an Janssen Pharmaceutical Ltd., Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010; 5:16.","DOI":"10.1186\/1750-1172-5-16"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mengel E, Klunemann HH, Lourenco CM, Hendriksz CJ, Sedel F, Walterfang M, Kolb SA. Niemann-Pick disease type C symptomatology: An expert-based clinical description. Orphanet J Rare Dis. 2013; 8:166.","DOI":"10.1186\/1750-1172-8-166"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Imrie J, Galani C, Gairy K, Lock K, Hunsche E. Cost of illness associated with Niemann-Pick disease type C in the UK. J Med Econ. 2009; 12:219-229.","DOI":"10.3111\/13696990903245863"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mengel E, Patterson MC, Chladek M, Guldberg C, \u013a Dali C, Symonds T, Lloyd-Price L, Mathieson T, Crowe J, Burbridge C. Impacts and burden of Niemann Pick type-C: A patient and caregiver perspective. Orphanet J Rare Dis. 2021; 16:493.","DOI":"10.1186\/s13023-021-02105-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F, NP-C Guidelines Working Group. Recommendations for the diagnosis and management of Niemann-Pick disease type C: An update. Mol Genet Metab. 2012; 106:330-344.","DOI":"10.1016\/j.ymgme.2012.03.012"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wassif CA, Cross JL, Iben J, Sanchez-Pulido L, Cougnoux A, Platt FM, Ory DS, Ponting CP, Bailey-Wilson JE, Biesecker LG, Porter FD. High incidence of unrecognized visceral\/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genet Med. 2016; 18:41-48.","DOI":"10.1038\/gim.2015.25"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Patterson MC, Mengel E, Vanier MT, Moneuse P, Rosenberg D, Pineda M. Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease type C: a final report of the NPC Registry. Orphanet J Rare Dis. 2020; 15:104.","DOI":"10.1186\/s13023-020-01363-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Burton BK, Ellis AG, Orr B, Chatlani S, Yoon K, Shoaff JR, Gallo D. Estimating the prevalence of Niemann-Pick disease type C (NPC) in the United States. Mol Genet Metab. 2021; 134:182-187.","DOI":"10.1016\/j.ymgme.2021.06.011"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Liang H, Zhan X, Wang Y, Maegawa GHB, Zhang H. Development and validation of a new genotype-phenotype correlation for Niemann-Pick disease type C1. J Inherit Metab Dis. 2024; 47:317-326.","DOI":"10.1002\/jimd.12705"},{"key":"10","unstructured":"10. European Medicines Agency. Miglustat. Summary of product characteristics. <i>https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavesca-epar-product-information_en.pdf<\/i> (accessed October 7, 2024)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lyseng-Williamson KA. Miglustat: A review of its use in Niemann-Pick disease type C. Drugs. 2014; 74:61-74.","DOI":"10.1007\/s40265-013-0164-6"},{"key":"12","unstructured":"12. Actelion Pharmaceuticals. Investigator&apos;s Brochure JNJ-66674140 Zavesca\u00ae (miglustat). 2020; pp. 123."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: A randomised controlled study. Lancet Neurol. 2007; 6:765-772.","DOI":"10.1016\/S1474-4422(07)70194-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994; 269:8362-8365.","DOI":"10.1016\/S0021-9258(17)37202-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Pineda M, Wraith JE, Mengel E, Sedel F, Hwu WL, Rohrbach M, Bembi B, Walterfang M, Korenke GC, Marquardt T, Luzy C, Giorgino R, Patterson MC. Miglustat in patients with Niemann-Pick disease type C (NP-C): A multicenter observational retrospective cohort study. Mol Genet Metab. 2009; 98:243-249.","DOI":"10.1016\/j.ymgme.2009.07.003"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Karimzadeh P, Tonekaboni SH, Ashrafi MR, <i>et al. <\/i>Effects of miglustat on stabilization of neurological disorder in Niemann-Pick disease type C: Iranian pediatric case series. J Child Neurol. 2013; 28:1599-1606.","DOI":"10.1177\/0883073812464526"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fecarotta S, Amitrano M, Romano A, Della Casa R, Bruschini D, Astarita L, Parenti G, Andria G. The videofluoroscopic swallowing study shows a sustained improvement of dysphagia in children with Niemann-Pick disease type C after therapy with miglustat. Am J Med Genet A. 2011; 155A:540-547.","DOI":"10.1002\/ajmg.a.33847"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Chien YH, Peng SF, Yang CC, Lee NC, Tsai LK, Huang AC, Su SC, Tseng CC, Hwu WL. Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C. J Inherit Metab Dis. 2013; 36:129-137.","DOI":"10.1007\/s10545-012-9479-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Heron B, Valayannopoulos V, Baruteau J, Chabrol B, Ogier H, Latour P, Dobbelaere D, Eyer D, Labarthe F, Maurey H, Cuisset JM, de Villemeur TB, Sedel F, Vanier MT. Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C. Orphanet J Rare Dis. 2012; 7:36.","DOI":"10.1186\/1750-1172-7-36"},{"key":"20","unstructured":"20. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice <i>https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_DraftGuideline_2023_0519.pdf<\/i> (accessed June 28, 2024)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Patterson MC, Di Bisceglie AM, Higgins JJ, Abel RB, Schiffmann R, Parker CC, Argoff CE, Grewal RP, Yu K, Pentchev PG, Brady RO, Barton NW. The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. Neurology. 1993; 43:61-64.","DOI":"10.1212\/WNL.43.1_Part_1.61"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Cariati I, Masuelli L, Bei R, Tancredi V, Frank C, D&apos;Arcangelo G. Neurodegeneration in Niemann-Pick type C disease: An updated review on pharmacological and non-pharmacological approaches to counteract brain and cognitive impairment. Int J Mol Sci. 2021; 22:6600.","DOI":"10.3390\/ijms22126600"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tirelli C, Rondinone O, Italia M, Mira S, Belmonte LA, De Grassi M, Guido G, Maggioni S, Mondoni M, Miozzo MR, Centanni S. The genetic basis, lung involvement, and therapeutic options in Niemann-Pick disease: A comprehensive review. Biomolecules. 2024; 14:211.","DOI":"10.3390\/biom14020211"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/13\/4\/13_2024.01056\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T05:02:31Z","timestamp":1733547751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/13\/4\/13_2024.01056\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2024.01056","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,30]]},"article-number":"2024.01056"}}